REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) in HR+, HER2-metastatic breast cancer (MBC).

CF Singer; D Egle; R Greil; L Ohler; Edgar Petru; Christoph Suppan; M Marhold; G Pfeiler; C Brunner; C Tinchon; S Halper; A Galid; U Pluschnig; F Haslbauer; M Hubalek; A Redl; J Flatschacher; M Hennebelle; B Mraz; R Bartsch

doi:10.1016/j.annonc.2020.03.272

REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) in HR+, HER2-metastatic breast cancer (MBC).

CF Singer
, D Egle
, R Greil
, L Ohler
, Edgar Petru
, Christoph Suppan
, M Marhold
, G Pfeiler
, C Brunner
, C Tinchon
, S Halper
, A Galid
, U Pluschnig
, F Haslbauer
, M Hubalek
, A Redl
, J Flatschacher
, M Hennebelle
, B Mraz
, R Bartsch

Research output: Contribution to journal › Conference abstract

1 Citation (Web of Science)

Original language	English
Journal	Annals of Oncology
DOIs	https://doi.org/10.1016/j.annonc.2020.03.272
Publication status	Published - 2020
Event	European Society for Medical Oncology Breast Cancer Virtual Meeting 2020 - online Duration: 23 May 2020 → 24 May 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Branches of science

305 Other Human Medicine, Health Sciences
301 Medical-Theoretical Sciences, Pharmacy
302 Clinical Medicine

DOI

10.1016/j.annonc.2020.03.272

Links

Web of Science

REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) in HR+, HER2-metastatic breast cancer (MBC).
Singer, C. (Author), Egle, D. (Author), Greil, R. (Author), Ohler, L. (Author), Petru, E. (Author), Suppan, C. (Author), Marhold, M. (Author), Pfeiler, G. (Author), Brunner, C. (Author), Tinchon, C. (Author), Halper, S. (Author), Galid, A. (Author), Pluschnig, U. (Author), Haslbauer, F. (Author), Hubalek, M. (Author), Redl, A. (Author), Flatschacher, J. (Author), Hennebelle, M. (Author), Mraz, B. (Author) & Bartsch, R. (Author)
2020
Activity: Talk, presentation or poster › Scientific talk or presentation › On site

Cite this

Singer, CF., Egle, D., Greil, R., Ohler, L., Petru, E., Suppan, C., Marhold, M., Pfeiler, G., Brunner, C., Tinchon, C., Halper, S., Galid, A., Pluschnig, U., Haslbauer, F., Hubalek, M., Redl, A., Flatschacher, J., Hennebelle, M., Mraz, B., & Bartsch, R. (2020). REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) in HR+, HER2-metastatic breast cancer (MBC). Annals of Oncology. https://doi.org/10.1016/j.annonc.2020.03.272

@article{2604a5dcb509429492102939b5d0af54,

title = "REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) in HR+, HER2-metastatic breast cancer (MBC).",

author = "CF Singer and D Egle and R Greil and L Ohler and Edgar Petru and Christoph Suppan and M Marhold and G Pfeiler and C Brunner and C Tinchon and S Halper and A Galid and U Pluschnig and F Haslbauer and M Hubalek and A Redl and J Flatschacher and M Hennebelle and B Mraz and R Bartsch",

year = "2020",

doi = "10.1016/j.annonc.2020.03.272",

language = "English",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

note = "European Society for Medical Oncology Breast Cancer Virtual Meeting 2020, ESMO BC 2020 ; Conference date: 23-05-2020 Through 24-05-2020",

}

Singer, CF, Egle, D, Greil, R, Ohler, L, Petru, E , Suppan, C, Marhold, M, Pfeiler, G, Brunner, C, Tinchon, C, Halper, S, Galid, A, Pluschnig, U, Haslbauer, F, Hubalek, M, Redl, A, Flatschacher, J, Hennebelle, M, Mraz, B & Bartsch, R 2020, 'REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) in HR+, HER2-metastatic breast cancer (MBC).', Annals of Oncology. https://doi.org/10.1016/j.annonc.2020.03.272

TY - JOUR

T1 - REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) in HR+, HER2-metastatic breast cancer (MBC).

AU - Singer, CF

AU - Egle, D

AU - Greil, R

AU - Ohler, L

AU - Petru, Edgar

AU - Suppan, Christoph

AU - Marhold, M

AU - Pfeiler, G

AU - Brunner, C

AU - Tinchon, C

AU - Halper, S

AU - Galid, A

AU - Pluschnig, U

AU - Haslbauer, F

AU - Hubalek, M

AU - Redl, A

AU - Flatschacher, J

AU - Hennebelle, M

AU - Mraz, B

AU - Bartsch, R

PY - 2020

Y1 - 2020

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000538879300152

U2 - 10.1016/j.annonc.2020.03.272

DO - 10.1016/j.annonc.2020.03.272

M3 - Conference abstract

SN - 0923-7534

JO - Annals of Oncology

JF - Annals of Oncology

T2 - European Society for Medical Oncology Breast Cancer Virtual Meeting 2020

Y2 - 23 May 2020 through 24 May 2020

ER -

REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) in HR+, HER2-metastatic breast cancer (MBC).

UN SDGs

Branches of science

DOI

Links

Activities

REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) in HR+, HER2-metastatic breast cancer (MBC).

Cite this